Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan/Cisplatin vs Pemetrexed/Cisplatin in Second-line NSCLC
NCT00614965Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Nov 2006
- Primary completion
- Mar 2010
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Hellenic Oncology Research Group. Started Nov 2006; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00614965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00614965.